Topline results from a phase 2b/3 clinical trial of blarcamesine for individuals with early-stage Alzheimer’s disease showed ...

Nearly one in two Americans will develop dementia in their lifetimes, according to New York University researchers who say ...

Gryphon Bio, Inc. has announced its pursuit of observational clinical studies with partners at multiple U.S. and ...

Delray Medical Center cut the ribbon on its newest high-tech machine that targets brain areas to treat movement disorders ...

Sleep disturbances encompass a broad range of disorders, such as insomnia, restless legs syndrome, parasomnias, sleep-disordered breathing, daytime ...

The number of US adults who will develop dementia each year is projected to increase from approximately 514,000 in 2020 to ...

The Florey Dementia Index (FDI) is valid for predicting the age of onset of mild cognitive impairment (MCI) and Alzhei ...

ProMIS Neurosciences Inc. (Nasdaq: PMN) (ProMIS), a clinical-stage biotechnology company focused on the generation and ...

TD Cowen analyst Joseph Thome has maintained their bullish stance on ITCI stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...

Having depression is known to increase a person’s risk of developing dementia, but depression is also an early indicator of ...

Mild chronic small vessel disease, or cerebral small vessel disease (CSVD), is an umbrella term for a range of conditions ...

The Phase Ia trial is designed to assess the company’s drug designed to target chemicals thought to be a cause of Alzheimer’s disease.